Sarepta Therapeutics, Inc.
NASDAQ:SRPTBiotechnology
+$0.29 today
- Market cap
- $1.56B
- Beta
- 0.20
- P/E (TTM)
- 27.8
- EPS (TTM)
- $0.62
Volume 1.86M
Average 3.08M
SRPT Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Sarepta Therapeutics, Inc.NASDAQ: SRPT
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $108.95M fell 18.5% year over year, behind the -17.3% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 15.1% from the prior quarter. Over 3 fiscal years it compounded at +2.0% a year.
Context
- Selling, general & admin amounted to 21.8% of revenue in FY2025, down 7.5 pp from a year earlier.
- Selling, general & admin increased in 2 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 16 analysts of $666.19M (+39.1%) for the fiscal year ending Dec 2026, a step up from the -14.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $108.95M-15.1% QoQ
- Last fiscal yearDec 2025
- $478.94M-14.1% YoY
- LTMMar 2026
- $467.04M-17.3% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 478.94M USD
- Year-over-year change
- -14.1%
- 4-year CAGR
- +14.1%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 478.94M | -14.1% |
| FY2024 | 2024-12-31 | 557.87M | +15.8% |
| FY2023 | 2023-12-31 | 481.87M | +6.7% |
| FY2022 | 2022-12-31 | 451.42M | +59.7% |
| FY2021 | 2021-12-31 | 282.66M | — |
Selling, General & Admin vs competitors
How SRPT compares with its peers on the latest reported figures
- SRPT's LTM Mar 2026 selling, general & admin of $467.04M is the 3rd highest of the 11 companies compared; the peer median is $85.16M.
- Its year-over-year change of -17.3% is the lowest of 11, against a peer median of +20.4%.
- Selling, general & admin amounts to 21.4% of revenue for SRPT, versus a peer median of 61.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.32B | +22.1% | +16.3% | 27.4% | |
| LTM Sep 2026 | $584.98M | +66.3% | +37.9% | 61.0% | |
| LTM Mar 2026 | $467.04M | -17.3% | +2.0% | 21.4% | |
| LTM Jun 2026 | $351.33M | +8.3% | +2.1% | 34.8% | |
| LTM Mar 2026 | $157.94M | +14.5% | +9.9% | 239.0% | |
| LTM Jun 2026 | $91.25M | +50.5% | +35.3% | — | |
| LTM Mar 2026 | $79.08M | +23.9% | +14.3% | 110.1% | |
| LTM Mar 2026 | $40.91M | +18.8% | +10.3% | — | |
| LTM Mar 2026 | $26.76M | +58.7% | +29.7% | — | |
| LTM Mar 2026 | $22.56M | +1.9% | +16.6% | — | |
| LTM Mar 2026 | $20.62M | +11.6% | +2.3% | — | |
| Peer median (excluding SRPT) | $85.16M | +20.4% | +15.3% | 61.0% | |
Competitors are the stored peer set for SRPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 701.89M | 933.01M | 1.24B | 1.9B | 2.2B |
| Cost of Revenue | 97.05M | 139.99M | 150.34M | 319.1M | 881.5M |
| Gross Profit | 604.84M | 793.02M | 1.09B | 1.58B | 1.32B |
| Gross Margin | 86.2% | 85.0% | 87.9% | 83.2% | 59.9% |
| Research & Development | 771.18M | 877.09M | 877.39M | 804.52M | 1.52B |
| Selling, General & Admin | 282.66M | 451.42M | 481.87M | 557.87M | 478.94M |
| Operating Expenses | 1.06B | 1.33B | 1.36B | 1.36B | 1.97B |
| Depreciation & Amortization | 38.02M | 41.86M | 44.4M | 37.72M | 44.52M |
| EBITDA | (317.41M) | (594.85M) | (453.69M) | 316.89M | (647.97M) |
| EBITDA Margin | -45.2% | -63.8% | -36.5% | 16.7% | -29.5% |
| Operating Income | (459.71M) | (536.2M) | (267.82M) | 218.08M | (657.77M) |
| Operating Margin | -65.5% | -57.5% | -21.5% | 11.5% | -29.9% |
| Interest Income | 511K | 27.72M | 85.97M | 71.77M | 19.57M |
| Interest Expense | 63.53M | 53.25M | 22.01M | 18.39M | 9.73M |
| Other Income / Expenses | 40.76M | (153.76M) | (252.27M) | 42.69M | (44.45M) |
| Income Before Tax | (418.95M) | (689.96M) | (520.1M) | 260.77M | (702.23M) |
| Pre-Tax Margin | -59.7% | -73.9% | -41.8% | 13.7% | -31.9% |
| Income Tax Expense | (168K) | 13.53M | 15.88M | 25.54M | 11.19M |
| Net Income | (418.78M) | (703.49M) | (535.98M) | 235.24M | (713.41M) |
| Net Margin | -59.7% | -75.4% | -43.1% | 12.4% | -32.5% |
| EPS (Basic) | (5.15) | (8.03) | (5.80) | 2.47 | (7.13) |
| EPS (Diluted) | (5.15) | (8.03) | (5.80) | 2.34 | (7.13) |
| Weighted Avg Shares | 81.26M | 87.56M | 92.4M | 95.08M | 104.79M |
| Weighted Avg Shares (Diluted) | 81.26M | 87.56M | 92.4M | 107.88M | 104.79M |
Sarepta Therapeutics, Inc.
NASDAQ:SRPT
Intrinsic Alpha fair value
Locked
Current Price
$14.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.